Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
Janux Therapeutics Inc (NASDAQ: JANX) closed the day trading at $17.11 up 7.88% from the previous closing price of $15.86. In other words, the price has increased by $7.88 from its previous closing price. On the day, 5.66 million shares were traded. JANX stock price reached its highest trading level at $17.37 during the session, while it also had its lowest trading level at $15.51.
Ratios:
For a better understanding of JANX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 35.86 and its Current Ratio is at 35.86. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
On September 17, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $47.
On September 10, 2025, Truist started tracking the stock assigning a Buy rating and target price of $100.Truist initiated its Buy rating on September 10, 2025, with a $100 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 01 ’25 when Meyer Andrew Hollman sold 3,333 shares for $32.98 per share. The transaction valued at 109,929 led to the insider holds 84,974 shares of the business.
BYRON C ROBINSON bought 63,125 shares of JANX for $1,033,743 on Dec 02 ’25. On Dec 01 ’25, another insider, ANDREW MEYER, who serves as the Officer of the company, bought 3,333 shares for $34.09 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JANX now has a Market Capitalization of 1029129024 and an Enterprise Value of 62795976. For the stock, the TTM Price-to-Sale (P/S) ratio is 102.91 while its Price-to-Book (P/B) ratio in mrq is 1.05. Its current Enterprise Value per Revenue stands at 6.28 whereas that against EBITDA is -0.442.
Stock Price History:
The Beta on a monthly basis for JANX is 2.88, which has changed by -0.7607843 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, JANX has reached a high of $71.71, while it has fallen to a 52-week low of $15.77. The 50-Day Moving Average of the stock is -36.14%, while the 200-Day Moving Average is calculated to be -35.80%.
Shares Statistics:
Over the past 3-months, JANX traded about 1.26M shares per day on average, while over the past 10 days, JANX traded about 2840330 shares per day. A total of 60.12M shares are outstanding, with a floating share count of 53.79M. Insiders hold about 10.56% of the company’s shares, while institutions hold 106.96% stake in the company. Shares short for JANX as of 1763078400 were 7131951 with a Short Ratio of 5.66, compared to 1760486400 on 8562496. Therefore, it implies a Short% of Shares Outstanding of 7131951 and a Short% of Float of 17.03.
Earnings Estimates
At present, 12.0 analysts are actively evaluating the performance of Janux Therapeutics Inc (JANX) in the stock market.The consensus estimate for the next quarter is -$0.71, with high estimates of -$0.56 and low estimates of -$1.06.
Analysts are recommending an EPS of between -$1.28 and -$2.56 for the fiscal current year, implying an average EPS of -$1.98. EPS for the following year is -$2.98, with 13.0 analysts recommending between -$2.38 and -$4.6.
Revenue Estimates
A total of 15 analysts have provided revenue estimates for JANX’s current fiscal year. The highest revenue estimate was $11M, while the lowest revenue estimate was $10M, resulting in an average revenue estimate of $10.07M. In the same quarter a year ago, actual revenue was $10.59M
